Clinicians discuss the prevalence and impact of major depressive disorder (MDD), highlighting the current therapeutic landscape and discussing new agents on the horizon.
EP. 1: Navigating Major Depressive Disorder (MDD): The Role of Glutamate
Experts discuss the significance of glutamate in major depressive disorder, highlighting its links to neuroplasticity and stress.
EP. 2: Glutamate's Rapid Impact: A New Approach to MDD Management
Clinicians discuss past treatment options compared to novel glutamate-modulating agents, highlighting their rapid onset of symptom relief.
EP. 3: Neurotransmitter Ballet: NMDA and AMPA in MDD Management
Experts highlight the role of NMDA and AMPA receptors in major depressive disorder (MDD) and how new therapies are targeting novel mechanisms of action.
EP. 4: Cognitive Wellness: The Potential of Glutamate Modulation for MDD
Clinicians discuss the effects of glutamate modulation on neuroplasticity, memory, and cognitive function, highlighting their role in improving overall wellness for their patients.
EP. 5: Targeting Glutamate Receptors in MDD Treatment
Experts continue their discussion on the role of glutamate receptors, explaining their role in stimulating neuroplasticity and neurogenesis.
EP. 6: Hopeful Horizons: The Potential of Rapid Acting Therapies in MDD
Clinicians discuss the particular benefits of rapid-acting agents for major depressive disorder (MDD), highlighting the gap glutamate-modulating agents fill in targeted therapies.
EP. 7: Shifting Paradigms: The Future Role of Rapid Acting Antidepressants
Experts discuss the need to review current clinical guidelines in light of the need for rapid-acting treatment, especially as first-line treatments for some patients.
EP. 8: Anhedonia and Cognitive Dysfunction: Glutamate Modulation's Impact
Experts discuss the impact of targeting glutamate receptors, highlighting its positive effects for patients with anhedonia.
EP. 9: Current Landscape of Rapid-Acting Therapies for MDD
Experts highlight the current and prospective therapies for patients with MDD, highlighting key similarities and differences in patient pathophysiology, drug onset of action, and overall therapeutic limitations.
EP. 10: Examining New Agents for MDD Treatment (AXS-05)
Clinicians begin their review of three new agents approved for the treatment of major depressive disorder (MDD).
EP. 11: Examining New Agents for MDD Treatment (Zuranolone)
Clinicians continue their discussion of three new agents approved for the treatment of major depressive disorder (MDD).
EP. 12: Examining New Agents for MDD Treatment (Esketemine)
Clinicians wrap up their discussion of three new agents approved for the treatment of major depressive disorder (MDD).
2 Clarke Drive Cranbury, NJ 08512